|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
Valuation Estimation |
EPS (Current/Estimated)
-3.60/3.83
|
Enterprise Value
1.01B
|
Balance Sheet |
Book Value Per Share
8.89
|
Cash Flow |
Cash Flow Yield
0.17
|
Income Statement |
Total Revenue
1.01B
|
Operating Revenue Per Share
19.76
|
Industry Comparison
|
||||||||||||||||||||||||||||||||||||||||||||||||
|

Industry overview quotes are at least 15 minutes delayed
Business Description
|
|||
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consistingof Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. The key revenue is generated through the commercial segmentwhich consists of NARCAN and other commercial products. |